Advertisement


Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study

2024 ASH Annual Meeting

Advertisement

Hannah Choe, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital, reviews results from a secondary analysis of the phase 2 AGAVE-201 study, which assessed axatilimab, an anti-colony stimulating factor 1 receptor monoclonal antibody, in the setting of chronic graft-versus-host disease (cGVHD). Dr. Choe reports on findings from the secondary analysis, which assessed the timing/dynamics of clinical and symptom responses in patients with cGVHD with axatilimab in AGAVE-201 (Abstract 98).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Agave 2.01 was an open label multicenter, randomized study of axatilimab at three different doses. This study met its primary endpoint with an NIH clinical response rate of 73% within the first six treatment cycles. It also met its key secondary endpoint with a seven point or more improvement in the modified Lee symptom scale of 55.1% of patients. In this analysis that we presented in the abstract at ASH 2024, we looked at those responders with NIH clinical response or mLSS symptom response. We evaluate the dynamics of these responses overall and by organ and also between the NIH clinical and symptoms scores. Responsive patients reflected the overall study population. There was heavy pre-treatment and also majority of patients with severe disease. The fastest responding organs by clinical responses were the upper GI tract, lower GI tract, joints, fascia, esophagus, and liver. With median responses seen 1.0 to 1.9 months. More than half of these responses were seen by day 56, if not day 84. The more fibrotic manifestations, which included the mouth, lungs, eyes, and skin, took longer to respond with median 2.1 to 3.2 months. But interestingly, we found that patients had symptom improvements as seen by improvements in their mLSS symptom scales faster with their NIH clinical responses in these slower responsive organs, including the mouth, lungs, and eyes, and trended towards significance with the skin. These responses were seen in the first one to two months. We now understand better how and when patients respond to axatilimab as assessed by clinicians with the NIH clinical response and patients from the patient reported outcomes from the modified Lee symptom scale. Importantly, patients responded with symptom improvements preceding that of the clinician, and this was seen particularly with the fibrotic manifestations, axatilimab, thus demonstrated rapid activity, not just by clinical responses, but also even more so with symptom responses sooner. And overall, it was well tolerated as seen in the overall AGAVE 201 study.

Related Videos

Hematologic Malignancies

John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib

John O. Mascarenhas, MD, of Icahn School of Medicine at Mount Sinai, discusses early results from the ongoing phase I/IB IMproveMF trial, which is evaluating the safety and activity of the novel combination of imetelstat and ruxolitinib in patients with intermediate- or high-risk myelofibrosis (Abstract 998).  

Leukemia

Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia

Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an inflammatory phenotype in driving clonal evolution in B-cell acute lymphoblastic leukemia. The new findings may indicate promising avenues for further research on treatment resistance and disease relapse (Abstract 633).

Lymphoma

Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

Maayan Levy, PhD, and Marco Ruella, MD, of the University of Pennsylvania, Perelman School of Medicine, discuss findings on whether ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models. The results of this study will be translated into a first-in-human clinical trial of BHB-supplementation during CAR-T 19 treatment for relapsed or refractory B cell lymphoma. The data were presented during the ASH Plenary Scientific Session (Abstract 4). 

Leukemia

Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-duration acalabrutinib/venetoclax—with or without obinutuzumab—with investigator’s choice of chemoimmunotherapy in fit patients with treatment-naïve chronic lymphocytic leukemia (CLL). According to Dr. Brown, this trial met its primary endpoint, with improved progression-free survival reported with this first all-oral fixed-duration regimen.

Hematologic Malignancies
Supportive Care

Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD

Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) symptom severity and MAGIC algorithm probabilities in patients with clinical and biomarker-defined low-risk GVHD to further risk-stratify patients into clinically meaningful groups (Abstract 380).

Advertisement

Advertisement




Advertisement